107 related articles for article (PubMed ID: 19300412)
21. Human tumor gangliosides inhibit murine immune responses in vivo.
Li R; Villacreses N; Ladisch S
Cancer Res; 1995 Jan; 55(2):211-4. PubMed ID: 7812945
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Kampasi H; Qazi GN; Sanyal U
J Exp Clin Cancer Res; 2003 Sep; 22(3):411-8. PubMed ID: 14582700
[TBL] [Abstract][Full Text] [Related]
23. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxicity in vitro and preliminary antitumor activity in vivo of a novel organotin compound.
Barbieri F; Viale M; Sparatore F; Favre A; Cagnoli M; Bruzzo C; Novelli F; Alama A
Anticancer Res; 2000; 20(2A):977-80. PubMed ID: 10810384
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
Matsumura T; Sussman JJ; Krinock RA; Chang AE; Shu S
Cancer Res; 1994 May; 54(10):2744-50. PubMed ID: 8168105
[TBL] [Abstract][Full Text] [Related]
26. Distribution of cycling T lymphocytes in blood and lymphoid organs during immune responses.
Vasseur F; Le Campion A; Pavlovitch JH; Pénit C
J Immunol; 1999 May; 162(9):5164-72. PubMed ID: 10227988
[TBL] [Abstract][Full Text] [Related]
27. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and anticancer activity of thiosemicarbazones.
Hu WX; Zhou W; Xia CN; Wen X
Bioorg Med Chem Lett; 2006 Apr; 16(8):2213-8. PubMed ID: 16458509
[TBL] [Abstract][Full Text] [Related]
29. Novel thiosemicarbazone derivatives as potential antitumor agents: Synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity.
Dilović I; Rubcić M; Vrdoljak V; Kraljević Pavelić S; Kralj M; Piantanida I; Cindrić M
Bioorg Med Chem; 2008 May; 16(9):5189-98. PubMed ID: 18358728
[TBL] [Abstract][Full Text] [Related]
30. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological activity of 3- and 5-amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone.
Liu MC; Lin TS; Cory JG; Cory AH; Sartorelli AC
J Med Chem; 1996 Jun; 39(13):2586-93. PubMed ID: 8691457
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of dimethoxydop-NU as a novel anti-tumor agent.
Mukherjee A; Dutta S; Sanyal U
J Exp Clin Cancer Res; 2007 Dec; 26(4):489-97. PubMed ID: 18365543
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Sharma M; Qazi GN; Sanyal U
Acta Pol Pharm; 2007; 64(1):27-33. PubMed ID: 17665847
[TBL] [Abstract][Full Text] [Related]
35. [Cytological and immunological aspects of the antitumor action of polyhexamethylene guanidine in BALB/c mice].
Baumanis EA; Birska IA; Zakenfeld GK; Volkova VV; Luksha UE
Eksp Onkol; 1989; 11(3):66-9. PubMed ID: 2752947
[TBL] [Abstract][Full Text] [Related]
36. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of phthalmustine, a new anticancer compound. II. Tumor inhibitory effect in murine Ehrlich ascites carcinoma and sarcoma-180.
Bhattacharya S; Ghosh M; Sadhu U; Dutta S; Sanyal U
Neoplasma; 1996; 43(3):209-13. PubMed ID: 8841510
[TBL] [Abstract][Full Text] [Related]
38. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
Narla RK; Chen CL; Dong Y; Uckun FM
Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
[TBL] [Abstract][Full Text] [Related]
39. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
40. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
